COST-EFFECTIVENESS ANALYSIS OF CAMRELIZUMAB VS. PLACEBO ADDED TO CHEMOTHERAPY AS FIRST-LINE THERAPY FOR ADVANCED OR METASTATIC ESOPHAGEAL SQUAMOUS CELL CARCINOMA IN CHINA

ObjectiveThe purpose of this cost-effectiveness analysis was to estimate the effects of adding camrelizumab to standard chemotherapy as Pre Workout Boosters the first-line treatment in patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC) on health and economic outcomes in China.MethodsA Markov model was developed to simula

Malignant mesothelioma (MM) is poorly responsive to systemic cytotoxic chemotherapy and invariably fatal.Here we describe a screen of 94 drugs in 15 exome-sequenced MM lines and the discovery of a subset defined by loss of function of the nuclear deubiquitinase BRCA associated protein-1 (BAP1) that demonstrate heightened sensitivity to TRAIL (tumou

BackgroundDigital technologies have afforded people living with multiple sclerosis (MS) access to telehealth consultations, diagnostic tools, and monitoring.Although health care professionals remain the most trusted source of information, the internet has emerged as a valuable resource for providing MS-related information, particularly during the C

Kristofer Skoglund,1 Ludvig Clase,2 Mikael Dellborg3 1Hallands Hospital Kungsbacka, Sweden, and Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; 2Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; 3Adult Congenital Heart Unit, Department of Medicine, Sahlgrenska University Hospital, Gothenburg, Sweden Background: A